Editorial
|
|
|
|
|
For quality treatment decisions
|
|
|
|
Marketing Authorisations
|
|
|
|
|
In chronic constipation: poorly documented risks
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cervical screening must remain a priority
|
|
|
|
|
|
|
|
|
|
Autologous chondrocyte implantation: more data needed
|
|
|
|
Adverse Effects
|
|
|
|
|
Use another NSAID
|
|
|
|
|
|
|
|
|
|
A follow-up cohort of 19 486 patients
|
|
|
|
|
|
|
|
|
|
|
|
No proven efficacy but a clear risk of seizures
|
|
|
|
|
|
|
|
|
|
Another reason not to use
|
|
|
|
Reviews
|
|
|
|
|
Adverse effects are a major factor in treatment choice
|
|
|
|
|
|
Outlook
|
|
|
|
|
2010 Prescrire annual report
|
|
|
|
|
|
|
|
|
|
57 proposals on how to get medicines policy back on track
|
|
|
|
|
|
|
|
|
|
Beware of commercially biased education
|
|
|
|
|
|
|
|